Skip to main content

Advertisement

SpringerLink
Log in

An inducible MAO-B mouse model of Parkinson’s disease: a tool towards better understanding basic disease mechanisms and developing novel therapeutics

  • Neurology and Preclinical Neurological Studies - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Several studies have suggested that increases in astrocytic monoamine oxidase B (MAO-B) levels in conjunction with Parkinson’s disease (PD) may contribute to subsequent neuropathology associated with the disorder. MAO-B inhibitors are currently widely used as symptomatic therapeutics for PD and, although somewhat controversial, these drugs may also exhibit disease-modifying properties. To obtain a better understanding of the potential role of MAO-B in disease neuropathology, we created an inducible astrocyte-specific transgenic MAO-B mouse model. Here, we summarize findings associated with this model, including neuropathological PD features associated with it.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Antkiewicz-Michaluk L (2002) Endogenous risk factors in Parkinson’s disease: dopamine and tetrahydroisoquinolines. Pol J Pharmacol 54(6):567–572

    CAS  PubMed  Google Scholar 

  • Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20(4):415–455

    Article  CAS  Google Scholar 

  • Bhat R, Crowe EP, Bitto A, Moh M, Katsetos CD, Garcia FU, Johnson FB, Trojanowski JQ, Sell C, Torres C (2012) Astrocyte senescence as a component of Alzheimer’s disease. PLoS One 7(9):e45069

    Article  CAS  Google Scholar 

  • Bitto A, Sell C, Crowe E, Lorenzini A, Malaguti M, Hrelia S, Torres C (2010) Stress-induced senescence in human and rodent astrocytes. Exp Cell Res 316(17):2961–2968

    Article  CAS  Google Scholar 

  • Borroni E, Bohrmann B, Grueninger F, Prinssen E, Nave S, Loetscher H, Chinta SJ, Rajagopalan S, Rane A, Siddiqui A, Ellenbroek B, Messer J, Pahler A, Andersen JK, Wyler R, Cesura AM (2017) Sembragiline: a novel, selective monoamine oxidase type B inhibitor for the treatment of Alzheimer’s disease. J Pharmacol Exp Ther 362(3):413–423

    Article  CAS  Google Scholar 

  • Bosoi CR, Rose CF (2009) Identifying the direct effects of ammonia on the brain. Metab Brain Dis 24(1):95–102

    Article  CAS  Google Scholar 

  • Burke WJ, Kumar VB, Pandey N, Panneton WM, Gan Q, Franko MW, O’Dell M, Li SW, Pan Y, Chung HD, Galvin JE (2008) Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 115(2):193–203

    Article  CAS  Google Scholar 

  • Chinta SJ, Lieu CA, Demaria M, Laberge RM, Campisi J, Andersen JK (2013) Environmental stress, ageing and glial cell senescence: a novel mechanistic link to Parkinson’s disease? J Intern Med 273(5):429–436

    Article  CAS  Google Scholar 

  • Chinta SJ, Woods G, Demaria M, Rane A, Zou Y, McQuade A, Rajagopalan S, Limbad C, Madden DT, Campisi J, Andersen JK (2018) Cellular senescence is induced by the environmental neurotoxin paraquat and contributes to neuropathology linked to Parkinson’s disease. Cell Rep 22(4):930–940

    Article  CAS  Google Scholar 

  • Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6(12):2853–2868

    Article  CAS  Google Scholar 

  • Danielson SR, Held JM, Schilling B, Oo M, Gibson BW, Andersen JK (2009) Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson’s disease. Anal Chem 81(18):7823–7828

    Article  CAS  Google Scholar 

  • Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39(6):889–909

    Article  CAS  Google Scholar 

  • de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5(6):525–535

    Article  Google Scholar 

  • Desagher S, Glowinski J, Premont J (1996) Astrocytes protect neurons from hydrogen peroxide toxicity. J Neurosci 16(8):2553–2562

    Article  CAS  Google Scholar 

  • Dunleavy DL (1973) Mood and sleep changes with monoamine-oxidase inhibitors. Proc R Soc Med 66(9):951

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ehrhart J, Zeevalk GD (2001) Hydrogen peroxide removal and glutathione mixed disulfide formation during metabolic inhibition in mesencephalic cultures. J Neurochem 77(6):1496–1507

    Article  CAS  Google Scholar 

  • Federico P, Zochodne DW (2001) Reversible parkinsonism and hyperammonemia associated with portal vein thrombosis. Acta Neurol Scand 103(3):198–200

    Article  CAS  Google Scholar 

  • Fowler JS, Wolf AP, MacGregor RR, Dewey SL, Logan J, Schlyer DJ, Langstrom B (1988) Mechanistic positron emission tomography studies: demonstration of a deuterium isotope effect in the monoamine oxidase-catalyzed binding of [11C]L-deprenyl in living baboon brain. J Neurochem 51(5):1524–1534

    Article  CAS  Google Scholar 

  • Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong R, Mash DC, Kopin IJ, Sharabi Y (2013) Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson’s disease. J Neurochem 126(5):591–603

    Article  CAS  Google Scholar 

  • Gossen M, Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89(12):5547–5551

    Article  CAS  Google Scholar 

  • Greenamyre JT, Cannon JR, Drolet R, Mastroberardino PG (2010) Lessons from the rotenone model of Parkinson’s disease. Trends Pharmacol Sci 31(4):141–142; author reply 142–143

    Article  CAS  Google Scholar 

  • Hartmann A (2004) Postmortem studies in Parkinson’s disease. Dial Clin Neurosci 6(3):281–293

    Google Scholar 

  • Hauser RA, Abler V, Eyal E, Eliaz RE (2016) Efficacy of rasagiline in early Parkinson’s disease: a meta-analysis of data from the TEMPO and ADAGIO studies. Int J Neurosci 126(10):942–946

    Article  CAS  Google Scholar 

  • Hirsch EC, Vyas S, Hunot S (2012) Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord 18(Suppl 1):S210–S212

    Article  Google Scholar 

  • Kang SS, Zhang Z, Liu X, Manfredsson FP, He L, Iuvone PM, Cao X, Sun YE, Jin L, Ye K (2017) alpha-Synuclein binds and sequesters PIKE-L into Lewy bodies, triggering dopaminergic cell death via AMPK hyperactivation. Proc Natl Acad Sci USA 114(5):1183–1188

    Article  CAS  Google Scholar 

  • Kang I, Chu CT, Kaufman BA (2018) The mitochondrial transcription factor TFAM in neurodegeneration: emerging evidence and mechanisms. FEBS Lett 592(5):793–811

    Article  CAS  Google Scholar 

  • Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676):605–608

    Article  CAS  Google Scholar 

  • Lecht S, Haroutiunian S, Hoffman A, Lazarovici P (2007) Rasagiline—a novel MAO B inhibitor in Parkinson’s disease therapy. Ther Clin Risk Manag 3(3):467–474

    CAS  PubMed  PubMed Central  Google Scholar 

  • Levitt P, Pintar JE, Breakefield XO (1982) Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 79(20):6385–6389

    Article  CAS  Google Scholar 

  • LeWitt PA (1994) Clinical trials of neuroprotection in Parkinson’s disease: long-term selegiline and alpha-tocopherol treatment. J Neural Transm Suppl 43:171–181

    CAS  PubMed  Google Scholar 

  • Lieu CA, Dewey CM, Chinta SJ, Rane A, Rajagopalan S, Batir S, Kim YH, Andersen JK (2014) Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model. Brain Res 1591:111–117

    Article  CAS  Google Scholar 

  • Lohle M, Reichmann H (2011) Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson’s disease. BMC Neurol 11:112

    Article  Google Scholar 

  • Magyar K, Szende B (2004) (−)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 25(1–2):233–242

    Article  CAS  Google Scholar 

  • Mallajosyula JK, Kaur D, Chinta SJ, Rajagopalan S, Rane A, Nicholls DG, Di Monte DA, Macarthur H, Andersen JK (2008) MAO-B elevation in mouse brain astrocytes results in Parkinson’s pathology. PLoS One 3(2):e1616

    Article  Google Scholar 

  • Marsden CD (1990) Parkinson’s disease. Lancet 335(8695):948–952

    Article  CAS  Google Scholar 

  • Marziniak M, Mossner R, Benninghoff J, Syagailo YV, Lesch KP, Sommer C (2004) Association analysis of the functional monoamine oxidase A gene promotor polymorphism in migraine. J Neural Transm (Vienna) 111(5):603–609

    Article  CAS  Google Scholar 

  • Merikangas KR, Merikangas JR (1995) Combination monoamine oxidase inhibitor and beta-blocker treatment of migraine, with anxiety and depression. Biol Psychiatry 38(9):603–610

    Article  CAS  Google Scholar 

  • Mombach JC, Bugs CA, Chaouiya C (2014) Modelling the onset of senescence at the G1/S cell cycle checkpoint. BMC Genom 15(Suppl 7):S7

    Article  Google Scholar 

  • Nedic G, Pivac N, Hercigonja DK, Jovancevic M, Curkovic KD, Muck-Seler D (2010) Platelet monoamine oxidase activity in children with attention-deficit/hyperactivity disorder. Psychiatry Res 175(3):252–255

    Article  CAS  Google Scholar 

  • Neuhaus JF, Baris OR, Hess S, Moser N, Schroder H, Chinta SJ, Andersen JK, Kloppenburg P, Wiesner RJ (2014) Catecholamine metabolism drives generation of mitochondrial DNA deletions in dopaminergic neurons. Brain 137(Pt 2):354–365

    Article  Google Scholar 

  • Nichols NR, Day JR, Laping NJ, Johnson SA, Finch CE (1993) GFAP mRNA increases with age in rat and human brain. Neurobiol Aging 14(5):421–429

    Article  CAS  Google Scholar 

  • Nonnekes J, Post B, Tetrud JW, Langston JW, Bloem BR (2018) MPTP-induced parkinsonism: an historical case series. Lancet Neurol 17(4):300–301

    Article  Google Scholar 

  • Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E, Investigators AS (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361(13):1268–1278

    Article  CAS  Google Scholar 

  • Parkinson Study Group (1998) Mortality in DATATOP: a multicenter trial in early Parkinson’s disease. Ann Neurol 43(3): 318–325

    Article  Google Scholar 

  • Pertusa M, Garcia-Matas S, Rodriguez-Farre E, Sanfeliu C, Cristofol R (2007) Astrocytes aged in vitro show a decreased neuroprotective capacity. J Neurochem 101(3):794–805

    Article  CAS  Google Scholar 

  • Plotegher N, Berti G, Ferrari E, Tessari I, Zanetti M, Lunelli L, Greggio E, Bisaglia M, Veronesi M, Girotto S, Dalla Serra M, Perego C, Casella L, Bubacco L (2017) DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Sci Rep 7:40699

    Article  CAS  Google Scholar 

  • Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, Olanow CW A. F. U.Investigators (2016) Long-term effects of rasagiline and the natural history of treated Parkinson’s disease. Mov Disord 31(10):1489–1496

    Article  CAS  Google Scholar 

  • Razygraev AV, Arutiunian AV (2008) Pineal gland and brain structures monoamine oxidase activity in rats of different age. Adv Gerontol 21(3):402–405

    CAS  PubMed  Google Scholar 

  • Riederer P, Laux G (2011) MAO-inhibitors in Parkinson’s Disease. Exp Neurobiol 20(1):1–17

    Article  Google Scholar 

  • Salminen A, Ojala J, Kaarniranta K, Haapasalo A, Hiltunen M, Soininen H (2011) Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. Eur J Neurosci 34(1):3–11

    Article  Google Scholar 

  • Samson JA, Gurrera RJ, Nisenson L, Schildkraut JJ (1995) Platelet monoamine oxidase activity and deficit syndrome schizophrenia. Psychiatry Res 56(1):25–31

    Article  CAS  Google Scholar 

  • Saura J, Richards JG, Mahy N (1994) Differential age-related changes of MAO-A and MAO-B in mouse brain and peripheral organs. Neurobiol Aging 15(4):399–408

    Article  CAS  Google Scholar 

  • Saura J, Andres N, Andrade C, Ojuel J, Eriksson K, Mahy N (1997) Biphasic and region-specific MAO-B response to aging in normal human brain. Neurobiol Aging 18(5):497–507

    Article  CAS  Google Scholar 

  • Schnaitman C, Erwin VG, Greenawalt JW (1967) The submitochondrial localization of monoamine oxidase. An enzymatic marker for the outer membrane of rat liver mitochondria. J Cell Biol 32(3):719–735

    Article  CAS  Google Scholar 

  • Seidl SE, Potashkin JA (2011) The promise of neuroprotective agents in Parkinson’s disease. Front Neurol 2:68

    Article  Google Scholar 

  • Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E, Sandhu S, Nel W, Rais A, Sandhu R, Ngu N, Sharma S (2013) Effect of diet on serotonergic neurotransmission in depression. Neurochem Int 62(3):324–329

    Article  CAS  Google Scholar 

  • Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, Dawson TM (2011) PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson’s disease. Cell 144(5):689–702

    Article  CAS  Google Scholar 

  • Shoulson I (1992) An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. Eur Neurol 32(Suppl 1):46–53

    Article  Google Scholar 

  • Shults CW (2005) Reexamination of the TEMPO study. Arch Neurol 62(8):1320 (author reply 1321)

    Article  Google Scholar 

  • Siddiqui A, Mallajosyula JK, Rane A, Andersen JK (2010) Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implications for early intervention on disease progression. Neurobiol Dis 40(2):444–448

    Article  CAS  Google Scholar 

  • Siddiqui A, Chinta SJ, Mallajosyula JK, Rajagopolan S, Hanson I, Rane A, Melov S, Andersen JK (2012a) Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson’s disease. Free Radic Biol Med 53(4):993–1003

    Article  CAS  Google Scholar 

  • Siddiqui A, Hanson I, Andersen JK (2012b) Mao-B elevation decreases parkin’s ability to efficiently clear damaged mitochondria: protective effects of rapamycin. Free Radic Res 46(8):1011–1018

    Article  CAS  Google Scholar 

  • Streit WJ, Mrak RE, Griffin WS (2004) Microglia and neuroinflammation: a pathological perspective. J Neuroinflamm 1(1):14

    Article  Google Scholar 

  • Szende B, Bokonyi G, Bocsi J, Keri G, Timar F, Magyar K (2001) Anti-apoptotic and apoptotic action of (−)-deprenyl and its metabolites. J Neural Transm (Vienna) 108(1):25–33

    Article  CAS  Google Scholar 

  • Turnquist C, Horikawa I, Foran E, Major EO, Vojtesek B, Lane DP, Lu X, Harris BT, Harris CC (2016) p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration. Cell Death Differ 23(9):1515–1528

    Article  CAS  Google Scholar 

  • Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230(4722):181–183

    Article  CAS  Google Scholar 

  • Westlund KN, Denney RM, Rose RM, Abell CW (1988) Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25(2):439–456

    Article  CAS  Google Scholar 

  • Weyler W, Hsu YP, Breakefield XO (1990) Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 47(3):391–417

    Article  CAS  Google Scholar 

  • Wu RM, Murphy DL, Chiueh CC (1996) Suppression of hydroxyl radical formation and protection of nigral neurons by l-deprenyl (selegiline). Ann N Y Acad Sci 786:379–390

    Article  CAS  Google Scholar 

  • Youdim MB, Weinstock M (2004) Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology 25(1–2):243–250

    Article  CAS  Google Scholar 

  • Zoccarato F, Cavallini L, Alexandre A (2004) Respiration-dependent removal of exogenous H2O2 in brain mitochondria: inhibition by Ca2+. J Biol Chem 279(6):4166–4174

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Buck Institute for Age Research, 8001 Redwood Blvd, Novato, CA, 9495, USA

    Manish Chamoli, Shankar J. Chinta & Julie K. Andersen

  2. Touro University, 1310 Club Dr, Vallejo, CA, 94592, USA

    Shankar J. Chinta

Authors
  1. Manish Chamoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shankar J. Chinta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julie K. Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie K. Andersen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chamoli, M., Chinta, S.J. & Andersen, J.K. An inducible MAO-B mouse model of Parkinson’s disease: a tool towards better understanding basic disease mechanisms and developing novel therapeutics. J Neural Transm 125, 1651–1658 (2018). https://doi.org/10.1007/s00702-018-1887-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-018-1887-z

Keywords

Search

Navigation